SEED Therapeutics Inc. has announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief ...

SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

For the past three decades, collaborations, deals and best practice exchanges on innovation and commercialisation have been a ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion. SiteOne, founded in 2010 ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 billion. This move has been done to expand the company’s neuroscience ...

(RTTNews) - Eli Lilly and Company (LLY), Tuesday announced an agreement regarding the acquisition of SiteOne Therapeutics, Inc., a private biotechnology company, for upto $1 billion in cash ...

Eli Lilly's (NYSE: LLY) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House. However, it's a much different story so far in Trump's ...

The company's lead drug recently completed an early-stage clinical trial, aiming to stop pain without setting off addiction. Thursday, June 12, 2025 Best Places to Work in the Bay Area Awards In ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...